Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Contrast Media Injectors Market $1.8 Billion by 2031

The global market for contrast media injectors expected to reach $1.8 billion by 2031, growing at the rate of 7.8% CAGR, driven by technological advancements, and increasing preference for imaging services worldwide.

  • Other factors driving the market growth include increasing use of medical imaging technologies such as computed tomography (CT), magnetic resonance imaging (MRI) and angiography procedures, as well as rising burden of chronic diseases.
Global Contrast Media Injectors Market

Contrast media injectors (CMI) are used to inject contrast media or contrast agents to enhance the blood and perfusion in tissues.

  • Contrast agents are widely used in clinical practice to improve diagnostic performance of medical imaging. Differentiation in organs and tissues of the body is frequently only possible with the use of contrast media.

The global injector market for contrast media likely to grow with a high number of imaging modalities and a good healthcare infrastructure. 

  • There have been several recent advances with contrast media injector technology, including cutting costs by reducing contrast waste and automated data collection for the dose a patient receives.
    • Automated injector systems not only precisely control the amount of contrast used; vendors have moved into the software/IT arena by offering personalized doses for patients using information from an electronic medical record (EMR) or picture archiving and communication system (PACS).
  • Syringeless power injectors have emerged in recent years as a solution to reduce contrast media waste.
    • In 2014, Guerbet launched FlowSens, its syringe-free injection system composed of a softbag injector and associated disposables, using a hydraulic, syringe-free injector to deliver contrast media. 
    • Bracco recently received approval from U.S. FDA to market the CT Express 3-D multi-patient injector platform, already popular in Europe, in the United States. 

The global contrast media injectors market report provides market size estimates ($million 2021 to 2031), market share, growth trends and forecast (CAGR% 2024 to 2031). 

The global contrast media injectors market segmented by product [(computed tomography injectors, magnetic resonance imaging injectors, cardiovascular or angiography injectors, others (x-ray, ultrasound and PET injectors)], consumables (syringes, tubes, others)], injector type (single head injector, dual-head injector, syringeless injector), application (interventional cardiology, interventional radiology, interventional neurology, interventional oncology, endovascular surgery), end user (hospitals, diagnostic specialty centers, others), and geography.

  • Based on the products, the CT-based injectors segment accounted for the largest share of total contrast media injectors market, driven by low-cost, time-saving operation, product version technology updates, increasing adoption rates and growing number of CT procedures, globally.
    • CT contrast agent injectors segment also predicated grow at the fastest CAGR during forecast period.
    • MRI is considered amongst the safest medical imaging procedures as it does not involve the use of any harmful imaging agents.
      • MRI-based contrast media injectors segment driven by high precision and accuracy.
  • In terms of applications, the interventional cardiology segment dominated the total contrast media injectors market and also predicted to witness the fastest growth rate throughout the forecast period.
    • The coronary angiography injectors form an integral part of the cardiac imaging and analysis system.
      • In addition, CMI increases peripheral venous blood flow and deliver contrast media to the central blood compartment faster, thereby saving critical time during cardiovascular procedures.

The global market for contrast media injectors research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • Geographically, the North America region led the total contrast media injectors market, followed by the Europe region, partly driven by increased adoption of information technology, updated imaging modalities and introduction of safer contrast media into the market.
    • On the other hand, the Asia Pacific CMI market projected to register the fastest growth rate over the forecast period, owing to increasing rate of imaging procedures (CT, MRI, etc.) and improving healthcare infrastructure.

The global market research report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and/or services offered, and recent trends in strategic management.

  • Guerbet acquired Mallinckrodt’s Contrast Media and Delivery Systems (CMDS) business in 2015. In 2016, Guerbet announced US-FDA clearance for the OptiOne single-head contrast delivery system, by acquiring Liebel-Flarsheim in 2015. 

Major competitors operating in the global contrast media injectors market and included in this report are APOLLO RT Co., Ltd., Bayer AG (Medrad, Inc.), Bracco Imaging S.p.A. (ACIST Medical Systems, Inc.), GE Healthcare (Vivid Imaging), Guerbet Group (Mallinckrodt Pharmaceuticals), Medtron AG, Nemoto Kyorindo Co., Ltd., Sino Medical-Device Technology Co., Ltd. (Sinomdt), Shenzhen Anke High-tech Co., Ltd., Shenzhen Seacrown Electromechanical Co., Ltd., and ulrich Medical GmbH & Co. KG.

  • Product
    • Computed Tomography (CT) Injectors
    • Magnetic Resonance (MRI) Injectors
    • Cardiovascular or Angiography Injectors
    • Others (X-ray, Ultrasound and PET Injectors)
    • Consumables
      • Syringes
      • Tubes
      • Others
  • Injector Type
    • Single Head Injector
    • Dual-Head Injector
    • Syringeless Injector
  • Application
    • Interventional Cardiology
    • Interventional Radiology
    • Interventional Neurology
    • Interventional Oncology
    • Endovascular Surgery
  • End User
    • Hospitals
    • Diagnostic Specialty Centers
    • Others
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • APOLLO RT Co., Ltd.
    • Bayer AG (Medrad, Inc.)
    • Bracco Imaging S.p.A. (ACIST Medical Systems, Inc.)
    • GE Healthcare (Vivid Imaging)
    • Guerbet Group (Mallinckrodt Pharmaceuticals)
    • Medtron AG
    • Nemoto Kyorindo Co., Ltd.
    • Sino Medical-Device Technology Co., Ltd. (Sinomdt)
    • Shenzhen Anke High-tech Co., Ltd.
    • Shenzhen Seacrown Electromechanical Co., Ltd.
    • ulrich Medical GmbH & Co. KG

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com